Silencing of cystatin SN abrogates cancer progression and stem cell properties in papillary thyroid carcinoma.

ABSTRACT: Papillary thyroid carcinoma (PTC) accounts for approximately 80% of total thyroid cancers worldwide. Although the prognosis for early-stage PTC is favorable, the 5-year survival rate of patients with late-stage PTC is still very poor. Cystatin SN (cystatin 1, CST1) facilitates the progression of multiple cancers, but its role in regulating PTC pathogenesis is still largely unknown. In this study, we measured the expression levels of CST1 in PTC clinical tissues and cell lines by real-time quantitative PCR and western blot analysis, and we performed gain- and loss-of-function experiments to examine the effects of CST1 on PTC cell growth, invasion, migration, epithelial-mesenchymal transition and stemness. Tumorigenicity was assessed using in vivo tumor-bearing nude mouse models. As expected

SUBMITTER: Ding J 

PROVIDER: S-EPMC8329778 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature